Literature DB >> 10642803

Characterisation of CTL directed towards non-inherited maternal alloantigens in human cord blood.

A Moretta1, F Locatelli, G Mingrat, G Rondini, D Montagna, P Comoli, S Gandossini, E Montini, M Labirio, R Maccario.   

Abstract

Allogeneic cord blood transplantation (CBT), especially from unrelated donors, is being increasingly used for treating paediatric patients with both malignant and non-malignant disorders. Recent clinical and experimental evidence suggests that human cord blood mononuclear cells (CBMC) may acquire in utero a state of tolerance towards non-inherited maternal antigens (NIMA). In order to better define this phenomenon, we measured, by means of a limiting dilution assay (LDA), the frequency of NIMA-specific CTL precursors (CTLp) in cord blood samples obtained from 13 healthy neonates. The immunophenotype of the effector cells recovered from LDA was also analysed. Data concerning both CTLp frequency and phenotype of effector cells were compared with those obtained stimulating CBMC with cells of paternal origin (NIPA) and adult PBMC with allogeneic targets. Results showed that cytotoxic cells directed towards cells of maternal origin could be detected in all cord blood samples tested. Phenotype analysis demonstrated that NIPA elicit the expansion of CD3+/CD8bright T cells, a phenotype associated with alloreactive CTL. By contrast, NIMA preferentially stimulated the expansion of CD3-/CD8dim+ cells, a phenotype associated with NK cells, which are known to be able, in certain clinical conditions, to kill allogeneic haematopoietic cells without causing GVHD. Thus, our results indicate that, when evaluated in a limiting dilution condition, NIMA-reactive cord blood cells are detectable and a preferential expansion of NK cells is observed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10642803     DOI: 10.1038/sj.bmt.1702054

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Biological individuality and the new frontiers of immunological tolerance in hematopoietic stem cell transplantation.

Authors:  Giuseppe Roberto Burgio; Marco Zecca; Patrizia Comoli; Rita Maccario
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

2.  The pendulum swings: Tolerance versus priming to NIMA.

Authors:  Shannon J Opiela; Becky Adkins
Journal:  Chimerism       Date:  2010 Jul-Sep

3.  Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors.

Authors:  Maria Antonietta Avanzini; Maria Ester Bernardo; Angela Maria Cometa; Cesare Perotti; Nadia Zaffaroni; Francesca Novara; Livia Visai; Antonia Moretta; Claudia Del Fante; Raffaella Villa; Lynne M Ball; Willem E Fibbe; Rita Maccario; Franco Locatelli
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

4.  A feasibility study on the prediction of acute graft-vs.-host disease before hematopoietic stem cell transplantation based on fetomaternal tolerance.

Authors:  Masahiro Hirayama; Eiichi Azuma; Tsuyoshi Ito; Yoshitaka Keida; Yoshihiro Komada
Journal:  Chimerism       Date:  2013-09-12

5.  Tolerogenic effect of non-inherited maternal antigens in hematopoietic stem cell transplantation.

Authors:  Masahiro Hirayama; Eiichi Azuma; Yoshihiro Komada
Journal:  Front Immunol       Date:  2012-05-25       Impact factor: 7.561

6.  The Distinct Immune Nature of the Fetal Inflammatory Response Syndrome Type I and Type II.

Authors:  Robert Para; Roberto Romero; Derek Miller; Jose Galaz; Bogdan Done; Azam Peyvandipour; Meyer Gershater; Li Tao; Kenichiro Motomura; Douglas M Ruden; Jenna Isherwood; Eunjung Jung; Tomi Kanninen; Roger Pique-Regi; Adi L Tarca; Nardhy Gomez-Lopez
Journal:  Immunohorizons       Date:  2021-09-14

7.  Do maternal cells trigger or perpetuate autoimmune diseases in children?

Authors:  Anne M Stevens
Journal:  Pediatr Rheumatol Online J       Date:  2007-05-16       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.